China Pharma (CPHI) Competitors

China Pharma logo
$0.49 +0.01 (+2.50%)
Closing price 03:58 PM Eastern
Extended Trading
$0.51 +0.02 (+4.07%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CPHI vs. UTZ, ICCC, CPIX, NMRA, and VTVT

Should you buy China Pharma stock or one of its competitors? China Pharma's main competitors and comparable companies include Utz Brands (UTZ), ImmuCell (ICCC), Cumberland Pharmaceuticals (CPIX), Neumora Therapeutics (NMRA), and vTv Therapeutics (VTVT). Companies are selected based on similarities in market, industry, and size.

How does China Pharma compare to Utz Brands?

Utz Brands (NYSE:UTZ) and China Pharma (NYSE:CPHI) are related companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

In the previous week, Utz Brands had 1 more articles in the media than China Pharma. MarketBeat recorded 3 mentions for Utz Brands and 2 mentions for China Pharma. Utz Brands' average media sentiment score of 1.02 beat China Pharma's score of 0.07 indicating that Utz Brands is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Utz Brands
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
China Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Utz Brands has higher revenue and earnings than China Pharma. Utz Brands is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Utz Brands$1.44B1.43$800K-$0.43N/A
China Pharma$3.91M5.41-$3.08M-$0.43N/A

Utz Brands currently has a consensus price target of $13.39, suggesting a potential downside of 6.23%. Given Utz Brands' stronger consensus rating and higher probable upside, equities research analysts clearly believe Utz Brands is more favorable than China Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Utz Brands
1 Sell rating(s)
9 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
China Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Utz Brands has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, China Pharma has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Utz Brands has a net margin of -2.67% compared to China Pharma's net margin of -85.56%. Utz Brands' return on equity of 7.64% beat China Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Utz Brands-2.67% 7.64% 3.62%
China Pharma -85.56%-63.93%-31.42%

96.0% of Utz Brands shares are owned by institutional investors. 12.7% of Utz Brands shares are owned by insiders. Comparatively, 6.4% of China Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Utz Brands beats China Pharma on 12 of the 15 factors compared between the two stocks.

How does China Pharma compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and China Pharma (NYSE:CPHI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

ImmuCell has higher revenue and earnings than China Pharma. China Pharma is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuCell$27.64M3.73-$1.04M$0.2056.65
China Pharma$3.91M5.41-$3.08M-$0.43N/A

13.5% of ImmuCell shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 6.4% of China Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ImmuCell has a net margin of 5.66% compared to China Pharma's net margin of -85.56%. ImmuCell's return on equity of 6.25% beat China Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuCell5.66% 6.25% 4.15%
China Pharma -85.56%-63.93%-31.42%

In the previous week, ImmuCell had 4 more articles in the media than China Pharma. MarketBeat recorded 6 mentions for ImmuCell and 2 mentions for China Pharma. ImmuCell's average media sentiment score of 0.94 beat China Pharma's score of 0.07 indicating that ImmuCell is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmuCell
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
China Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

ImmuCell has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, China Pharma has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmuCell
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
China Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

ImmuCell beats China Pharma on 11 of the 14 factors compared between the two stocks.

How does China Pharma compare to Cumberland Pharmaceuticals?

China Pharma (NYSE:CPHI) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cumberland Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

China Pharma has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market.

Cumberland Pharmaceuticals has higher revenue and earnings than China Pharma. China Pharma is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Pharma$3.91M5.41-$3.08M-$0.43N/A
Cumberland Pharmaceuticals$44.52M1.95-$2.84M$4.491.29

Cumberland Pharmaceuticals has a net margin of 274.38% compared to China Pharma's net margin of -85.56%. Cumberland Pharmaceuticals' return on equity of -19.50% beat China Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
China Pharma-85.56% -63.93% -31.42%
Cumberland Pharmaceuticals 274.38%-19.50%-8.12%

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 6.4% of China Pharma shares are held by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than China Pharma. MarketBeat recorded 3 mentions for Cumberland Pharmaceuticals and 2 mentions for China Pharma. Cumberland Pharmaceuticals' average media sentiment score of 0.79 beat China Pharma's score of 0.07 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
China Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cumberland Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Cumberland Pharmaceuticals beats China Pharma on 12 of the 14 factors compared between the two stocks.

How does China Pharma compare to Neumora Therapeutics?

China Pharma (NYSE:CPHI) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

China Pharma has higher revenue and earnings than Neumora Therapeutics. China Pharma is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Pharma$3.91M5.41-$3.08M-$0.43N/A
Neumora TherapeuticsN/AN/A-$236.93M-$1.23N/A

Neumora Therapeutics has a consensus target price of $7.17, indicating a potential upside of 2,042.50%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than China Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Neumora Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

47.7% of Neumora Therapeutics shares are held by institutional investors. 6.4% of China Pharma shares are held by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Neumora Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Neumora Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
China Pharma-85.56% -63.93% -31.42%
Neumora Therapeutics N/A -260.78%-121.51%

In the previous week, Neumora Therapeutics had 5 more articles in the media than China Pharma. MarketBeat recorded 7 mentions for Neumora Therapeutics and 2 mentions for China Pharma. Neumora Therapeutics' average media sentiment score of 0.65 beat China Pharma's score of 0.07 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
China Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Neumora Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

China Pharma has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 3.12, meaning that its share price is 212% more volatile than the broader market.

Summary

Neumora Therapeutics beats China Pharma on 10 of the 15 factors compared between the two stocks.

How does China Pharma compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and China Pharma (NYSE:CPHI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

China Pharma has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
vTv Therapeutics$1.02M67.97-$26.97M-$0.92N/A
China Pharma$3.91M5.41-$3.08M-$0.43N/A

vTv Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. vTv Therapeutics' return on equity of -10.15% beat China Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
vTv TherapeuticsN/A -10.15% -8.65%
China Pharma -85.56%-63.93%-31.42%

In the previous week, China Pharma had 1 more articles in the media than vTv Therapeutics. MarketBeat recorded 2 mentions for China Pharma and 1 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.09 beat China Pharma's score of 0.07 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
vTv Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
China Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

vTv Therapeutics currently has a consensus price target of $55.83, indicating a potential upside of 222.92%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe vTv Therapeutics is more favorable than China Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
China Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

vTv Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, China Pharma has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

17.5% of vTv Therapeutics shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by insiders. Comparatively, 6.4% of China Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

vTv Therapeutics beats China Pharma on 10 of the 17 factors compared between the two stocks.

Get China Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CPHI vs. The Competition

MetricChina PharmaPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$21.17M$13.74B$7.82B$23.17B
Dividend YieldN/A2.58%2.47%3.82%
P/E Ratio-1.1426.5832.7624.41
Price / Sales5.417.298.563.22
Price / CashN/A15.6321.0115.54
Price / Book0.705.424.463.65
Net Income-$3.08M$2.88B$3.52B$1.07B
7 Day Performance-10.71%-4.10%-5.47%-3.74%
1 Month Performance-30.69%-5.08%-4.57%-2.47%
1 Year Performance-67.20%-7.47%-1.79%6.03%

China Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CPHI
China Pharma
N/A$0.49
+2.5%
N/A-67.7%$21.17M$3.91MN/A221
UTZ
Utz Brands
2.3816 of 5 stars
$14.26
+0.0%
$13.39
-6.1%
+35.9%$2.05B$1.44BN/A3,300
ICCC
ImmuCell
1.1459 of 5 stars
$10.22
+0.3%
N/A+111.5%$92.55M$30.68M127.7773
CPIX
Cumberland Pharmaceuticals
1.5441 of 5 stars
$6.63
+8.3%
N/A+146.9%$91.70M$44.52M1.4893
NMRA
Neumora Therapeutics
3.0719 of 5 stars
$0.43
-8.5%
$6.57
+1,417.7%
-86.1%$88.88MN/AN/A63

Related Companies and Tools


This page (NYSE:CPHI) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners